TrialThe New England journal of medicine2012
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.
Srdan Verstovsek et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
1,098 papers cite itlatest 60 shown
this paperpooled ittrialcites it